US20020077315A1 - Bioadhesive antibacterial wound healing composition - Google Patents

Bioadhesive antibacterial wound healing composition Download PDF

Info

Publication number
US20020077315A1
US20020077315A1 US09/978,152 US97815201A US2002077315A1 US 20020077315 A1 US20020077315 A1 US 20020077315A1 US 97815201 A US97815201 A US 97815201A US 2002077315 A1 US2002077315 A1 US 2002077315A1
Authority
US
United States
Prior art keywords
composition
pyruvate
acid
vitamin
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/978,152
Inventor
Sau-Spence Leung
Alain Martin
Robert Leone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/978,152 priority Critical patent/US20020077315A1/en
Publication of US20020077315A1 publication Critical patent/US20020077315A1/en
Priority to US10/925,548 priority patent/US20050020537A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/225Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28Polysaccharides or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023Polysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Definitions

  • This invention pertains to therapeutic bioadhesive wound-healing compositions useful for treating wounds. More particularly, the bioadhesive wound-healing compositions comprise pullulan and wound-healing agents and/or metabolites thereof. This invention also pertains to methods for preparing and using the bioadhesive wound-healing compositions and the pharmaceutical products in which the therapeutic compositions may be used.
  • Wounds are internal or external bodily injuries or lesions caused by physical means, such as mechanical, chemical, viral, bacterial, or thermal means, which disrupt the normal continuity of structures.
  • Such bodily injuries include, e.g., contusions, wounds in which the skin is unbroken, incisions, wounds in which the skin is broken by a cutting instrument, and lacerations, wounds in which the skin is broken by a dull or blunt instrument.
  • U.S. Pat. No. 5,856,364 to Martin discloses a therapeutic antiviral wound-healing composition comprising an antiviral agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,692,302 to Martin et al. discloses a razor cartridge comprising a wound-healing composition delivery system fixed to the cartridge.
  • the wound-healing composition comprises effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,674,912 to Martin discloses a sunscreen wound-healing composition comprising a sunscreen agent, an anti-inflammatory agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,663,208 to Martin discloses an anti-fungal wound-healing composition
  • an anti-fungal agent and a wound-healing composition effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,658,957 to Martin discloses an immunostimulating wound-healing composition
  • an immunostimulating agent comprising an immunostimulating agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,658,956 to Leung and Martin discloses a bioadhesive wound-healing composition
  • a bioadhesive agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,652,274 to Martin discloses a therapeutic wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,648,380 to Martin discloses an anti-inflammatory wound-healing composition comprising an anti-inflammatory agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,646,190 to Martin discloses an acne treating wound-healing composition useful for the topical treatment of acne vulgaris tretinoin and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,641,814 to Martin discloses an antikeratolytic wound-healing composition comprising an antikeratolytic agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,633,285 to Martin discloses a cytoprotective wound-healing composition comprising a cytotoxic agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,614,561 to Martin discloses an antihistamine wound-healing composition comprising an antihistamine and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,602,183 to Martin et al. discloses a dermatological wound-healing composition useful to minimize and treat diaper comprising a therapeutically effective amount of a buffering agent to maintain the pH of the composition and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids.
  • U.S. Pat. No. 5,722,942 to Tanaka et al. discloses wound covering materials suitable for protection and treatment of wounds.
  • the materials comprise: (a) 1 part by weight of glucomannan; (b) 0.20-0.99 part by weight of a solubility modifier comprising pullulan or carrageenan; (c) 0.10-12 parts by weight of a physiologically acceptable adhesive polymer base; and (d) 0.20-20 parts by weight of at least one plasticizer selected from the group consisting of polyhydric alcohols, sugar alcohols, monosaccharides, disaccharides and oligosaccharides.
  • the materials are provided in the form of a film or a laminate of a film and another sheet material.
  • U.S. Pat. No. 5,618,799 to Inagi et al. discloses a powder preparation for healing damaged skin, which comprises: (a) 50-90wt. % sucrose; (b) 0.5-10wt. % povidone-iodine; and (c) a water-soluble polymer selected from the group consisting of polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acid and salts thereof, pullulan, carboxyvinyl polymers, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose and salts thereof.
  • U.S. Pat. No. 4,844,898 to Komori et al. discloses a wound-healing preparation which comprises 50-90 wt. % of a sugar, 0.5-10 wt. % of povidone-iodine, 1-20 wt. % of water, 0.1-5 wt. % of an agent for imparting an appropriate consistency and stability selected from polysaccharides and derivatives thereof, and a buffer in an amount sufficient to adjust the pH of the preparation to 3.56.
  • the polysaccharide can be, e.g., dextrin, gum arabic, pullulan, chondroitin sulfate, methylcellulose, sodium carboxymethylcellulose and the like.
  • U.S. Pat. No. 5,518,902 to Ozaki et al. discloses high pullulan content products, such as ointments and cosmetic packs.
  • the products can include a variety of ingredients in addition to pullulan, such as other polysaccharides, polyhydric alcohols, and antiseptics.
  • U.S. Pat. No. 5,411,945 to Ozaki et al. discloses a pullulan binder and products produced therewith, including a facial pack.
  • the products can include a variety of ingredients in addition to pullulan, such as other polysaccharides, antibacterial agents, pharmaceutically active substances and biologically active substances.
  • the invention provides a bioadhesive composition comprising pullulan, pyruvate, an antioxidant, and a mixture of saturated and unsaturated fatty acids adapted to resuscitate injured mammalian cells. Also provided is a method for treating a wound, wherein a bioadhesive composition of the invention is applied to the wound.
  • the bioadhesive composition of the invention comprises pullulan, pyruvate, an antioxidant, and a mixture of saturated and unsaturated fatty acids.
  • pullulan acts as a surprisingly effective vehicle for topically administering the active ingredients.
  • compositions of the invention preferably comprise pullulan in an amount of about 0.1 to about 80 wt. %, preferably about 40 to about 80 wt. % of the total weight of the composition.
  • pyruvate forms are suitable for use in the invention.
  • the pyruvate is preferably selected from the group consisting of pyruvic acid, lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, methyl pyruvate, ⁇ -ketoglutaric acid, pharmaceutically acceptable salts of pyruvic acid, prodrugs of pyruvic acid, and mixtures thereof. More preferably, the pyruvate is sodium pyruvate. Pyruvate is preferably present in the composition in an amount of about 10 to about 50 wt. % of the total weight of the composition.
  • a suitable antioxidant is preferably selected from the group consisting of all forms of Vitamin A; all forms of carotene; all forms of Vitamin C; all forms of Vitamin E; Vitamin E esters which readily undergo hydrolysis to Vitamin E; prodrugs of Vitamin A, carotene, Vitamin C, and Vitamin E; pharmaceutically acceptable salts of Vitamin A, carotene, Vitamin C, and Vitamin E; and mixtures thereof. More preferably, the antioxidant is Vitamin E acetate. The antioxidant is preferably present in an amount of about 0.1 to about 40 wt. % of the total weight of the composition.
  • the mixture of saturated and unsaturated fatty acids preferably comprises animal and vegetable fats and waxes. More preferably, the fatty acid mixture includes fats selected from the group consisting of human fat, chicken fat, cow fat, sheep fat, horse fat, pig fat, and whale fat.
  • the fatty acid mixture preferably comprises lauric acid, myristic acid, myristoleic acid, pentadecanoic acid, palmitic acid, palmitoleic acid, margaric acid, margaroleic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidic acid, and gadoleic acid.
  • the mixture of saturated and unsaturated fatty acids is preferably present in an amount of about 10 to about 50 wt. % of the total weight of the composition.
  • composition of the invention can further comprise water, pharmaceutically active agents, additional film-forming agents, plasticizing agents, additional flavoring agents, cooling agents, surfactants, stabilizing agents, emulsifying agents, thickening agents, binding agents, coloring agents, sweeteners, fragrances and the like.
  • the composition is preferably in the form of a film, which can be employed as a physiologically acceptable vehicle for administering pharmaceutically active agents through the skin or open wounds of a patient as it adheres thereto.
  • physiologically acceptable as used herein is intended to encompass compounds, which upon administration to a patient, are adequately tolerated without causing undue negative side-effects.
  • pharmaceutically active agents as used herein is intended to encompass agents that promote a structural and/or functional change in and/or on bodies to which they have been administered. These agents are not particularly limited; however, they should be physiologically acceptable and compatible with the film.
  • Suitable pharmaceutically active agents include, but are not limited to: immunostimulating agents (BetafectinTM), antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, tretinoin, sunscreen agents, dermatological agents, topical antihistamine agents, antibacterial agents, other bioadhesive agents, respiratory bursting inhibitors (lactic acid, adenosine), inhibitors of prostaglandin synthesis (ibuprofen, aspirin, indomethacin, meclofenomic acid, retinoic acid, padimate O, meclomen, oxybenzone), steroidal anti-inflammatory agents (corticosteroids including synthetic analogs), antimicrobial agents (Neosporin® ointment, silvadine, triclosan), antiseptic agents, anesthetic agents (pramoxine hydrochloride, lidocaine, benzocaine), cell nutrient media, bum relief medications, sun burn medications, acne preparations, insect bite and
  • Preferred antimicrobial agents include the essential oils (i.e., thymol, methyl salicylate, menthol and eucalyptol), copper gluconate, triclosan, polymyxin B sulfate, bacitracin zinc, and neomycin sulfate.
  • a particularly preferred wound-healing composition of the invention includes pullulan, pyruvate, an antioxidant, a mixture of saturated and unsaturated fatty acids, polymyxin B sulfate, bacitracin zinc, and neomycin sulfate.
  • the polymyxin B sulfate is present in an amount of about 1000 to about 15,000 units/gm
  • the bacitracin zinc is present in an amount of about 100 to about 1,500 units/gm
  • the neomycin sulfate is present in an amount of about 1 to about 15 mg/gm.
  • the composition of the invention is preferably provided in the form of a film that adheres on contact to moist skin. Due to the relatively high oil content in the film, it is preferable to avoid substantial amounts of humectant in the film (and more preferable to have no humectant in the film), so as to avoid producing an overly moist, self-adhering film. In particular, it is preferred to formulate the film with a plasticizing agent other than glycerin, which is also a humectant. If the film includes a sweetener, it is preferable to use a sweetener other than sorbitol, which is a mild humectant.
  • Preferred plasticizing agents include triacetin in amounts ranging from about 0 to about 20 wt. %, preferably about 0 to about 2 wt. %.
  • Other suitable plasticizing agents include monoacetin and diacetin.
  • Preferred cooling agents include physcool, in amounts ranging from about 0.001 to about 2.0 wt. %, preferably about 0.2 to about 0.4 wt. %.
  • Other suitable cooling agents include WS3 and the like.
  • Preferred surfactants include Polysorbate 80 and Atlas 3000 (Atmos 300) in amounts ranging from about 0.5 to about 15 wt. %, preferably about 2 to about 5 wt. %.
  • Other suitable surfactants include pluronic acid, sodium lauryl sulfate, and the like.
  • Preferred stabilizing agents include xanthan gum, locust bean gum and carrageenan, in amounts ranging from about 0 to about 10 wt. %, preferably about 0.01 to about 2 wt. %.
  • Other suitable stabilizing agents include guar gum and the like.
  • Preferred emulsifying agents include triethanolamine stearate, quaternary ammonium compounds, acacia, gelatin, lecithin, bentonite, veegum, and the like, in amounts ranging from about 0 to about 5 wt. %, preferably about 0.01 to about 0.7 wt. %.
  • Preferred thickening agents include methylcellulose, carboxyl methylcellulose, and the like, in amounts ranging from about 0 to about 20 wt. %, preferably about 0.01 to about 5 wt. %.
  • Preferred binding agents include starch, in amounts ranging from about 0 to about 10 wt. %, preferably about 0.01 to about 2 wt. %.
  • Preferred film formers include pullulan, in amounts ranging from about 0.1 to about 80 wt. %, preferably about 30 to about 70 wt. %.
  • Other suitable film formers include polyvinyl alcohol, suitable cellulose, and the like.
  • Suitable sweeteners that can be included are those well-known in the art, including both natural and artificial sweeteners. Suitable sweeteners include, e.g.:
  • water-soluble sweetening agents such as monosaccharides, disaccharides and polysaccharides such as xylose, ribose, glucose (dextrose), mannose, galactose, fructose (levulose), sucrose (sugar), maltose, invert sugar (a mixture of fructose and glucose derived from sucrose), partially hydrolyzed starch, corn syrup solids, dihydrochalcones, monellin, steviosides, and glycyrrhizin;
  • B. water-soluble artificial sweeteners such as the soluble saccharin salts, i.e., sodium or calcium saccharin salts, cyclamate salts, the sodium, ammonium or calcium salt of 3,4-dihydro-6-methyl-1,2,3-oxathiazine4-one-2, 2-dioxide, the potassium salt of 3,4-dihydro6-methyl-1,2,3-oxathiazine4-one-2,2-dioxide (acesulfame-K), the free acid form of saccharin, and the like;
  • soluble saccharin salts i.e., sodium or calcium saccharin salts, cyclamate salts
  • C. dipeptide based sweeteners such as L-aspartic acid derived sweeteners, such as L-aspartyl-L-phenylalanine methyl ester (aspartame) and materials described in U.S. Pat. No.
  • water-soluble sweeteners derived from naturally occurring water-soluble sweeteners such as a chlorinated derivative of ordinary sugar (sucrose), known, for example, under the product description of sucralose; and
  • E. protein based sweeteners such as thaumatoccous danielli (Thaumatin I and II).
  • auxiliary sweetener is utilized to provide the level of sweetness desired for a particular composition, and this amount will vary with the sweetener selected. This amount will normally be 0.1% to about 10% by weight of the composition when using an easily extractable sweetener.
  • the water-soluble sweeteners described in category A above are usually used in amounts of about 0. 1 to about 10 wt. %, and preferably in amounts of about 2 to about 5 wt. %.
  • Some of the sweeteners in category A e.g., glycyrrhizin
  • categories B-E due to the sweeteners' known sweetening ability.
  • sweeteners described in categories B-E are generally used in amounts of about 0.1 to about 10 wt. %, with about 2 to about 8 wt. % being preferred and about 3 to about 6 wt. % being most preferred. These amounts may be used to achieve a desired level of sweetness independent from the flavor level achieved from any optional flavor oils used. Of course, sweeteners need not be added to films intended for non-oral administration.
  • flavorings that can be used include those known to the skilled artisan, such as, natural and artificial flavors. These flavorings may be chosen from synthetic flavor oils and flavoring aromatics, and/or oils, oleo resins and extracts derived from plants, leaves, flowers, fruits and so forth, and combinations thereof.
  • Representative flavor oils include: spearmint oil, cinnamon oil, peppermint oil, clove oil, bay oil, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, and oil of bitter almonds.
  • artificial, natural or synthetic fruit flavors such as vanilla, and citrus oil, including lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so forth.
  • flavors include mints such as peppermint, artificial vanilla, cinnamon derivatives, and various fruit flavors, whether employed individually or in admixture.
  • Flavorings such as aldehydes and esters including cinnamyl acetate, cinnamaldehyde, citral, diethylacetal, dihydrocarvyl acetate, eugenyl formate, p-methylanisole, and so forth may also be used.
  • any flavoring or food additive such as those described in Chemicals Used in Food Processing, publication 1274 by the National Academy of Sciences, pages 63-258, may be used.
  • aldehyde flavorings include, but are not limited to acetaldehyde (apple); benzaldehyde (cherry, almond); cinnamic aldehyde (cinnamon); citral, i.e., alpha citral (lemon, lime); neral, i.e.
  • beta citral lemon, lime
  • decanal orange, lemon
  • ethyl vanillin vanilla, cream
  • heliotropine i.e., piperonal (vanilla, cream); vanillin (vanilla, cream); alpha-amyl cinnamaldehyde (spicy fruity flavors); butyraldehyde (butter, cheese); valeraldehyde (butter, cheese); citronellal (modifies, many types); decanal (citrus fruits); aldehyde C-8 (citrus fruits); aldehyde C-9 (citrus fruits); aldehyde C-12 (citrus fruits); 2-ethyl butyraldehyde (berry fruits); hexenal, i.e.
  • trans-2 berry fruits
  • tolyl aldehyde cherry, almond
  • veratraldehyde vanilla
  • 2,6-dimethyl-5-heptenal i.e. melonal (melon)
  • 2-6-dimethyloctanal green fruit
  • 2-dodecenal citrus, mandarin
  • the amount of flavoring employed is normally a matter of preference subject to such factors as flavor type, individual flavor, and strength desired. Thus, the amount may be varied in order to obtain the result desired in the final product. Such variations are within the capabilities of those skilled in the art without the need for undue experimentation. In general, amounts of about 0.1 to about 30 wt. % are useable with amounts of about 10 to about 25 wt. % being preferred.
  • compositions of this invention can also contain coloring agents or colorants.
  • the coloring agents are used in amounts effective to produce the desired color.
  • the coloring agents useful in the present invention include pigments such as titanium dioxide, which may be incorporated in amounts of up to about 5 wt. %, and preferably less than about 1 wt. %.
  • Colorants can also include natural food colors and dyes suitable for food, drug and cosmetic applications. These colorants are known as FD&C dyes and lakes.
  • the materials acceptable for the foregoing spectrum of use are preferably water-soluble, and include FD&C Blue No. 2, which is the disodium salt of 5,5-indigotindisulfonic acid. Similarly, the dye known as Green No.
  • Methods for preparing films according to the invention are capable of encapsulating the oil ingredients within the film-forming matrix and maintaining the integrity of the film, even when the film contains oils in amounts of 10 wt. % or more.
  • the film-forming ingredients are mixed and hydrated with water separately from the water-soluble ingredients, which are mixed in aqueous solution separately from the organic ingredients (i.e., oils) and surfactants.
  • the final formulation is preferably produced by mixing the film-forming phase with the aqueous phase, then mixing in the organic phase, which includes surfactants, such as Polysorbate 80 and Atmos 300 (i.e., Atlas 3000).
  • the resulting formulation is cast on a suitable substrate and dried to form a film.
  • the film is preferably air-dried or dried under warm air and cut to a desired dimension, packaged and stored.
  • the film preferably contains about 3% to about 8% moisture after drying.
  • the film-forming phase can include pullulan and stabilizing agents such as xanthan gum, locust bean gum and carrageenan. These ingredients are mixed and then hydrated in water for about 2 to about 48 hours to form a gel. The water is heated to a temperature of about 25 to about 45+ C. to promote hydration. The amount of water is about 40 to 80 % of the gel. The resulting hydrated gel is then chilled to a temperature of about 20 to about 30° C. for about 2 to about 48 hours. The water is preferably deionized.
  • pullulan and stabilizing agents such as xanthan gum, locust bean gum and carrageenan.
  • the aqueous phase can include ingredients such as coloring agent(s), copper gluconate and sweetener.
  • the water is preferably deionized and the amount of water used is about 5 to about 80 wt. % of the final gel mixture.
  • sodium saccharine and copper gluconate are both ingredients in the formulation, it is preferable to dissolve them separately in solution to avoid precipitation.
  • the preferred method of producing films comprises: (a) dissolving the water-soluble ingredients in water to form an aqueous mixture; (b) mixing the film-forming ingredients together in powder form to form a powder mixture; (c) adding the powder mixture to the aqueous mixture to form a hydrated polymer gel; (d) stirring the hydrated polymer at room temperature for about 1 to about 48 hours; (e) mixing the hydrophobic ingredients and surfactants to form an oil phase; (f) adding the oil phase to the hydrated polymer gel and mixing until uniform; (g) casting the uniform mixture on a suitable substrate; and (h) drying the cast mixture to form a film.
  • the preferred method can be conducted without hydrating the film-forming ingredients in hot water. Heating the ingredients increases energy costs in the manufacturing process. Moreover, heating results in undesirable losses of volatile ingredients to evaporation, which also affects the composition of the formulation. Further, mixing the oils in two steps minimizes the amount of flavor lost.
  • the film-forming ingredients can be hydrated and mixed without heating due to an ionic effect known as the Donnan equilibrium. Hydrating the film-forming agents in the presence of electrolytes in solution effectively lowers the viscosity of the polymer gel being formed, thus increasing the efficiency of the hydrating process.
  • the electrolytes are provided by the water-soluble ingredients of the formulation, which are dissolved in the hydration solution prior to addition of the film-forming ingredients.
  • NUMBER INGREDIENT WEIGHT (grams) 1 Xanthan Gum 0.0385 2 Locust Bean Gum 0.0770 3 Carrageenan 0.3850 4 Pullulan 18.5000 5 Deionized Water 84.2500 6 Mineral Oil 3.000 7 Sodium Pyruvate 0.2200 8 Vitamin E 0.2200 9 Rendered Chicken Fat 0.2200 10 Polysorbate 80 0.4000 11 Atlas 3000/Atmos 300 0.4000 12 Triclosan 0.0500
  • Ingredients 1-4 were dry mixed together and then added to ingredient 5 with further mixing to provide a gel phase.
  • Ingredients 6-12 were mixed to uniformity in a separate container to provide an oil phase. The oil phase was then added to the gel phase with mixing and stored overnight.
  • NUMBER INGREDIENT WEIGHT (grams) 1 Xanthan Gum 0.035 2 Locust Bean Gum 0.070 3 Carrageenan 0.350 4 Pullulan 18.000 5 Deionized Water 75.755 6 Tween 80 0.400 7 Atlas 3000/Atmos 300 0.400 8 Polymyxin B Sulfate 0.0035 9 Bacitracin Zinc 0.0319 10 Neomycin Sulfate 0.030 11 Petrolatum, White 4.135 12 Vitamin E 0.100 13 Cocoa Butter 0.120 14 Olive Oil 0.180 15 Cottonseed Oil 0.300 16 Sodium Pyruvate 0.100
  • Ingredients 1-4 were dry mixed together and then added to ingredient 5 with further mixing to provide a gel phase.
  • Ingredients 8-16 were added to the gel phase in the form of 5.0 grams of NeosporinTM (Warner-Lambert Company, Morris Plains, N.J.) along with ingredients 6-7. The ingredients were mixed, poured on a mold and cast to form a film of a desired thickness at room temperature. The film was dried under warm air and cut to a desired dimension for testing.
  • NeosporinTM Warner-Lambert Company, Morris Plains, N.J.
  • the resulting film was not difficult to remove from the backing, but adhered to wet skin well.
  • the film dried to a clear and shiny protective film on the skin.
  • NUMBER INGREDIENT WEIGHT (grams) 1 Xanthan Gum 0.0385 2 Locust Bean Gum 0.077 3 Carrageenan 0.385 4 Pullulan 18.5 5 Deionized Water 54.25 6 Deionized Water 30 7 BHT (hydroxybutyl toluene) 0.03 8 Mineral Oil 3.0 9 Lidocaine 1.2 10 Polysorbate 80 0.4 11 Atlas 3000/Atmos 300 0.4
  • Ingredients 1-4 were dry mixed together and then added to ingredient 5 with further mixing to provide a gel phase.
  • Ingredients 6-7 were mixed together in a separate container to provide an aqueous phase.
  • Ingredients 8-11 were mixed to uniformity in a separate container to provide an oil phase. The aqueous phase was added to the gel phase, and then the oil phase was added to the gel/aqueous phase mixture with mixing.
  • the mixture was further mixed, poured on a mold and cast to form a film of a desired thickness at room temperature.
  • the film was dried under warm air and cut to a desired dimension.
  • NUMBER INGREDIENT WEIGHT (grams) 1 Xanthan Gum 0.0385 2 Locust Bean Gum 0.077 3 Carrageenan 0.385 4 Pullulan 18.5 5 Deionized Water 54.25 6 Copper Gluconate 0.4 7 Deionized Water 30 8 Mineral Oil 3.0 9 Sodium Pyruvate 0.22 10 Vitamin E 0.22 11 Rendered Chicken Fat 0.22 12 Polysorbate 80 0.4 13 Atlas 3000/Atmos 300 0.4
  • Ingredients 1-4 were dry mixed together and then added to ingredient 5 with further mixing to provide a gel phase.
  • Ingredients 6-7 were mixed together in a separate container to provide an aqueous phase.
  • Ingredients 8-13 were mixed to uniformity in a separate container to provide an oil phase. The aqueous phase was added to the gel phase, and then the oil phase was added to the gel/aqueous phase mixture with mixing.
  • the mixture was further mixed, poured on a mold and cast to form a film of a desired thickness at room temperature.
  • the film was dried under warm air and cut to a desired dimension.

Abstract

A bioadhesive wound-healing composition includes pullulan, pyruvate, an antioxidant, and a mixture of saturated and unsaturated fatty acids. The composition can be provided in the form of a film that does not self-adhere. The composition can include additional medicinal agents, such as polymyxin B sulfate, bacitracin zinc, and neomycin sulfate. Methods for producing the composition and methods for treating wounds with the composition are also disclosed.

Description

    FIELD OF THE INVENTION
  • This invention pertains to therapeutic bioadhesive wound-healing compositions useful for treating wounds. More particularly, the bioadhesive wound-healing compositions comprise pullulan and wound-healing agents and/or metabolites thereof. This invention also pertains to methods for preparing and using the bioadhesive wound-healing compositions and the pharmaceutical products in which the therapeutic compositions may be used. [0001]
  • BACKGROUND OF THE INVENTION
  • Wounds are internal or external bodily injuries or lesions caused by physical means, such as mechanical, chemical, viral, bacterial, or thermal means, which disrupt the normal continuity of structures. Such bodily injuries include, e.g., contusions, wounds in which the skin is unbroken, incisions, wounds in which the skin is broken by a cutting instrument, and lacerations, wounds in which the skin is broken by a dull or blunt instrument. [0002]
  • A wide variety of products have been developed that enhance the body's ability to heal itself when wounded. These products typically function by medicating the wound, isolating the wound from infectious agents, and/or by binding the wound to prevent wound growth and to minimize the gap that the body's natural repair mechanisms must bridge to heal the wound. [0003]
  • For example, U.S. Pat. No. 5,856,364 to Martin discloses a therapeutic antiviral wound-healing composition comprising an antiviral agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids. [0004]
  • U.S. Pat. No. 5,692,302 to Martin et al. discloses a razor cartridge comprising a wound-healing composition delivery system fixed to the cartridge. The wound-healing composition comprises effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids. [0005]
  • U.S. Pat. No. 5,674,912 to Martin discloses a sunscreen wound-healing composition comprising a sunscreen agent, an anti-inflammatory agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids. [0006]
  • U.S. Pat. No. 5,663,208 to Martin discloses an anti-fungal wound-healing composition comprising an anti-fungal agent and a wound-healing composition effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids. [0007]
  • U.S. Pat. No. 5,658,957 to Martin discloses an immunostimulating wound-healing composition comprising an immunostimulating agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids. [0008]
  • U.S. Pat. No. 5,658,956 to Leung and Martin discloses a bioadhesive wound-healing composition comprising a bioadhesive agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids. [0009]
  • U.S. Pat. No. 5,652,274 to Martin discloses a therapeutic wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids. [0010]
  • U.S. Pat. No. 5,648,380 to Martin discloses an anti-inflammatory wound-healing composition comprising an anti-inflammatory agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids. [0011]
  • U.S. Pat. No. 5,646,190 to Martin discloses an acne treating wound-healing composition useful for the topical treatment of acne vulgaris tretinoin and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids. [0012]
  • U.S. Pat. No. 5,641,814 to Martin discloses an antikeratolytic wound-healing composition comprising an antikeratolytic agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids. [0013]
  • U.S. Pat. No. 5,633,285 to Martin discloses a cytoprotective wound-healing composition comprising a cytotoxic agent and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids. [0014]
  • U.S. Pat. No. 5,614,561 to Martin discloses an antihistamine wound-healing composition comprising an antihistamine and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin E acetate; and a mixture of saturated and unsaturated fatty acids. [0015]
  • U.S. Pat. No. 5,602,183 to Martin et al. discloses a dermatological wound-healing composition useful to minimize and treat diaper comprising a therapeutically effective amount of a buffering agent to maintain the pH of the composition and a wound-healing composition comprising effective amounts of pyruvate; an antioxidant, preferably Vitamin B acetate; and a mixture of saturated and unsaturated fatty acids. [0016]
  • The foregoing Martin patents do not disclose wound-healing compositions comprising pullulan, unlike the following patents. [0017]
  • U.S. Pat. No. 5,722,942 to Tanaka et al. discloses wound covering materials suitable for protection and treatment of wounds. The materials comprise: (a) 1 part by weight of glucomannan; (b) 0.20-0.99 part by weight of a solubility modifier comprising pullulan or carrageenan; (c) 0.10-12 parts by weight of a physiologically acceptable adhesive polymer base; and (d) 0.20-20 parts by weight of at least one plasticizer selected from the group consisting of polyhydric alcohols, sugar alcohols, monosaccharides, disaccharides and oligosaccharides. The materials are provided in the form of a film or a laminate of a film and another sheet material. [0018]
  • U.S. Pat. No. 5,618,799 to Inagi et al. discloses a powder preparation for healing damaged skin, which comprises: (a) 50-90wt. % sucrose; (b) 0.5-10wt. % povidone-iodine; and (c) a water-soluble polymer selected from the group consisting of polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acid and salts thereof, pullulan, carboxyvinyl polymers, methylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose and salts thereof. [0019]
  • U.S. Pat. No. 4,844,898 to Komori et al. discloses a wound-healing preparation which comprises 50-90 wt. % of a sugar, 0.5-10 wt. % of povidone-iodine, 1-20 wt. % of water, 0.1-5 wt. % of an agent for imparting an appropriate consistency and stability selected from polysaccharides and derivatives thereof, and a buffer in an amount sufficient to adjust the pH of the preparation to 3.56. The polysaccharide can be, e.g., dextrin, gum arabic, pullulan, chondroitin sulfate, methylcellulose, sodium carboxymethylcellulose and the like. [0020]
  • U.S. Pat. No. 5,518,902 to Ozaki et al. discloses high pullulan content products, such as ointments and cosmetic packs. The products can include a variety of ingredients in addition to pullulan, such as other polysaccharides, polyhydric alcohols, and antiseptics. [0021]
  • U.S. Pat. No. 5,411,945 to Ozaki et al. discloses a pullulan binder and products produced therewith, including a facial pack. The products can include a variety of ingredients in addition to pullulan, such as other polysaccharides, antibacterial agents, pharmaceutically active substances and biologically active substances. [0022]
  • Despite the existence in the prior art of wound-healing compositions containing pullulan, there is still room for improvement in such compositions, and in processes for making them. [0023]
  • All references cited herein are incorporated herein by reference in their entireties. [0024]
  • SUMMARY OF THE INVENTION
  • The invention provides a bioadhesive composition comprising pullulan, pyruvate, an antioxidant, and a mixture of saturated and unsaturated fatty acids adapted to resuscitate injured mammalian cells. Also provided is a method for treating a wound, wherein a bioadhesive composition of the invention is applied to the wound. [0025]
  • DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
  • The bioadhesive composition of the invention comprises pullulan, pyruvate, an antioxidant, and a mixture of saturated and unsaturated fatty acids. Although the Martin patents teach the wound-healing effectiveness of a combination of pyruvate, antioxidant and a mixture of fatty acids, the inventors have discovered that pullulan acts as a surprisingly effective vehicle for topically administering the active ingredients. [0026]
  • Compositions of the invention preferably comprise pullulan in an amount of about 0.1 to about 80 wt. %, preferably about 40 to about 80 wt. % of the total weight of the composition. [0027]
  • A variety of pyruvate forms are suitable for use in the invention. The pyruvate is preferably selected from the group consisting of pyruvic acid, lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, methyl pyruvate, α-ketoglutaric acid, pharmaceutically acceptable salts of pyruvic acid, prodrugs of pyruvic acid, and mixtures thereof. More preferably, the pyruvate is sodium pyruvate. Pyruvate is preferably present in the composition in an amount of about 10 to about 50 wt. % of the total weight of the composition. [0028]
  • A suitable antioxidant is preferably selected from the group consisting of all forms of Vitamin A; all forms of carotene; all forms of Vitamin C; all forms of Vitamin E; Vitamin E esters which readily undergo hydrolysis to Vitamin E; prodrugs of Vitamin A, carotene, Vitamin C, and Vitamin E; pharmaceutically acceptable salts of Vitamin A, carotene, Vitamin C, and Vitamin E; and mixtures thereof. More preferably, the antioxidant is Vitamin E acetate. The antioxidant is preferably present in an amount of about 0.1 to about 40 wt. % of the total weight of the composition. [0029]
  • The mixture of saturated and unsaturated fatty acids preferably comprises animal and vegetable fats and waxes. More preferably, the fatty acid mixture includes fats selected from the group consisting of human fat, chicken fat, cow fat, sheep fat, horse fat, pig fat, and whale fat. The fatty acid mixture preferably comprises lauric acid, myristic acid, myristoleic acid, pentadecanoic acid, palmitic acid, palmitoleic acid, margaric acid, margaroleic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, arachidic acid, and gadoleic acid. The mixture of saturated and unsaturated fatty acids is preferably present in an amount of about 10 to about 50 wt. % of the total weight of the composition. [0030]
  • The composition of the invention can further comprise water, pharmaceutically active agents, additional film-forming agents, plasticizing agents, additional flavoring agents, cooling agents, surfactants, stabilizing agents, emulsifying agents, thickening agents, binding agents, coloring agents, sweeteners, fragrances and the like. The composition is preferably in the form of a film, which can be employed as a physiologically acceptable vehicle for administering pharmaceutically active agents through the skin or open wounds of a patient as it adheres thereto. [0031]
  • The expression “physiologically acceptable” as used herein is intended to encompass compounds, which upon administration to a patient, are adequately tolerated without causing undue negative side-effects. [0032]
  • The expression “pharmaceutically active agents” as used herein is intended to encompass agents that promote a structural and/or functional change in and/or on bodies to which they have been administered. These agents are not particularly limited; however, they should be physiologically acceptable and compatible with the film. Suitable pharmaceutically active agents include, but are not limited to: immunostimulating agents (Betafectin™), antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, tretinoin, sunscreen agents, dermatological agents, topical antihistamine agents, antibacterial agents, other bioadhesive agents, respiratory bursting inhibitors (lactic acid, adenosine), inhibitors of prostaglandin synthesis (ibuprofen, aspirin, indomethacin, meclofenomic acid, retinoic acid, padimate O, meclomen, oxybenzone), steroidal anti-inflammatory agents (corticosteroids including synthetic analogs), antimicrobial agents (Neosporin® ointment, silvadine, triclosan), antiseptic agents, anesthetic agents (pramoxine hydrochloride, lidocaine, benzocaine), cell nutrient media, bum relief medications, sun burn medications, acne preparations, insect bite and sting medications, wound cleansers, wound dressings, scar reducing agents (vitamin E), and the like, and mixtures thereof, to further enhance the proliferation and resuscitation rate of mammalian cells. [0033]
  • Preferred antimicrobial agents include the essential oils (i.e., thymol, methyl salicylate, menthol and eucalyptol), copper gluconate, triclosan, polymyxin B sulfate, bacitracin zinc, and neomycin sulfate. [0034]
  • A particularly preferred wound-healing composition of the invention includes pullulan, pyruvate, an antioxidant, a mixture of saturated and unsaturated fatty acids, polymyxin B sulfate, bacitracin zinc, and neomycin sulfate. Preferably, the polymyxin B sulfate is present in an amount of about 1000 to about 15,000 units/gm, the bacitracin zinc is present in an amount of about 100 to about 1,500 units/gm, and the neomycin sulfate is present in an amount of about 1 to about 15 mg/gm. [0035]
  • The composition of the invention is preferably provided in the form of a film that adheres on contact to moist skin. Due to the relatively high oil content in the film, it is preferable to avoid substantial amounts of humectant in the film (and more preferable to have no humectant in the film), so as to avoid producing an overly moist, self-adhering film. In particular, it is preferred to formulate the film with a plasticizing agent other than glycerin, which is also a humectant. If the film includes a sweetener, it is preferable to use a sweetener other than sorbitol, which is a mild humectant. [0036]
  • Preferred plasticizing agents include triacetin in amounts ranging from about 0 to about 20 wt. %, preferably about 0 to about 2 wt. %. Other suitable plasticizing agents include monoacetin and diacetin. [0037]
  • Preferred cooling agents include physcool, in amounts ranging from about 0.001 to about 2.0 wt. %, preferably about 0.2 to about 0.4 wt. %. Other suitable cooling agents include WS3 and the like. [0038]
  • Preferred surfactants include Polysorbate 80 and Atlas 3000 (Atmos 300) in amounts ranging from about 0.5 to about 15 wt. %, preferably about 2 to about 5 wt. %. Other suitable surfactants include pluronic acid, sodium lauryl sulfate, and the like. [0039]
  • Preferred stabilizing agents include xanthan gum, locust bean gum and carrageenan, in amounts ranging from about 0 to about 10 wt. %, preferably about 0.01 to about 2 wt. %. Other suitable stabilizing agents include guar gum and the like. [0040]
  • Preferred emulsifying agents include triethanolamine stearate, quaternary ammonium compounds, acacia, gelatin, lecithin, bentonite, veegum, and the like, in amounts ranging from about 0 to about 5 wt. %, preferably about 0.01 to about 0.7 wt. %. [0041]
  • Preferred thickening agents include methylcellulose, carboxyl methylcellulose, and the like, in amounts ranging from about 0 to about 20 wt. %, preferably about 0.01 to about 5 wt. %. [0042]
  • Preferred binding agents include starch, in amounts ranging from about 0 to about 10 wt. %, preferably about 0.01 to about 2 wt. %. [0043]
  • Preferred film formers include pullulan, in amounts ranging from about 0.1 to about 80 wt. %, preferably about 30 to about 70 wt. %. Other suitable film formers include polyvinyl alcohol, suitable cellulose, and the like. [0044]
  • Suitable sweeteners that can be included are those well-known in the art, including both natural and artificial sweeteners. Suitable sweeteners include, e.g.: [0045]
  • A. water-soluble sweetening agents such as monosaccharides, disaccharides and polysaccharides such as xylose, ribose, glucose (dextrose), mannose, galactose, fructose (levulose), sucrose (sugar), maltose, invert sugar (a mixture of fructose and glucose derived from sucrose), partially hydrolyzed starch, corn syrup solids, dihydrochalcones, monellin, steviosides, and glycyrrhizin; [0046]
  • B. water-soluble artificial sweeteners such as the soluble saccharin salts, i.e., sodium or calcium saccharin salts, cyclamate salts, the sodium, ammonium or calcium salt of 3,4-dihydro-6-methyl-1,2,3-oxathiazine4-one-2, 2-dioxide, the potassium salt of 3,4-dihydro6-methyl-1,2,3-oxathiazine4-one-2,2-dioxide (acesulfame-K), the free acid form of saccharin, and the like; [0047]
  • C. dipeptide based sweeteners, such as L-aspartic acid derived sweeteners, such as L-aspartyl-L-phenylalanine methyl ester (aspartame) and materials described in U.S. Pat. No. 3,492,131, L-alpha-aspartyl-N-(2,2,4,4-tetramethyl-3-thietanyl)-D-alaninamide hydrate, methyl esters of L-aspartyl-L-phenylglycerin and L-aspartyl-L-2,5,dihydrophenyl-glycine, L-aspartyl-2,5-dihydro- L-phenylalanine, L-aspartyl-L-(1-cyclohexyen)-alanine, and the like; [0048]
  • D. water-soluble sweeteners derived from naturally occurring water-soluble sweeteners, such as a chlorinated derivative of ordinary sugar (sucrose), known, for example, under the product description of sucralose; and [0049]
  • E. protein based sweeteners such as thaumatoccous danielli (Thaumatin I and II). [0050]
  • In general, an effective amount of auxiliary sweetener is utilized to provide the level of sweetness desired for a particular composition, and this amount will vary with the sweetener selected. This amount will normally be 0.1% to about 10% by weight of the composition when using an easily extractable sweetener. The water-soluble sweeteners described in category A above, are usually used in amounts of about 0. 1 to about 10 wt. %, and preferably in amounts of about 2 to about 5 wt. %. Some of the sweeteners in category A (e.g., glycyrrhizin) can be used in amounts set forth for categories B-E below due to the sweeteners' known sweetening ability. In contrast, the sweeteners described in categories B-E are generally used in amounts of about 0.1 to about 10 wt. %, with about 2 to about 8 wt. % being preferred and about 3 to about 6 wt. % being most preferred. These amounts may be used to achieve a desired level of sweetness independent from the flavor level achieved from any optional flavor oils used. Of course, sweeteners need not be added to films intended for non-oral administration. [0051]
  • The flavorings that can be used include those known to the skilled artisan, such as, natural and artificial flavors. These flavorings may be chosen from synthetic flavor oils and flavoring aromatics, and/or oils, oleo resins and extracts derived from plants, leaves, flowers, fruits and so forth, and combinations thereof. Representative flavor oils include: spearmint oil, cinnamon oil, peppermint oil, clove oil, bay oil, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, and oil of bitter almonds. Also useful are artificial, natural or synthetic fruit flavors such as vanilla, and citrus oil, including lemon, orange, grape, lime and grapefruit and fruit essences including apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so forth. These flavorings can be used individually or in admixture. Commonly used flavors include mints such as peppermint, artificial vanilla, cinnamon derivatives, and various fruit flavors, whether employed individually or in admixture. Flavorings such as aldehydes and esters including cinnamyl acetate, cinnamaldehyde, citral, diethylacetal, dihydrocarvyl acetate, eugenyl formate, p-methylanisole, and so forth may also be used. Generally, any flavoring or food additive, such as those described in Chemicals Used in Food Processing, publication 1274 by the National Academy of Sciences, pages 63-258, may be used. Further examples of aldehyde flavorings include, but are not limited to acetaldehyde (apple); benzaldehyde (cherry, almond); cinnamic aldehyde (cinnamon); citral, i.e., alpha citral (lemon, lime); neral, i.e. beta citral (lemon, lime); decanal (orange, lemon); ethyl vanillin (vanilla, cream); heliotropine, i.e., piperonal (vanilla, cream); vanillin (vanilla, cream); alpha-amyl cinnamaldehyde (spicy fruity flavors); butyraldehyde (butter, cheese); valeraldehyde (butter, cheese); citronellal (modifies, many types); decanal (citrus fruits); aldehyde C-8 (citrus fruits); aldehyde C-9 (citrus fruits); aldehyde C-12 (citrus fruits); 2-ethyl butyraldehyde (berry fruits); hexenal, i.e. trans-2 (berry fruits); tolyl aldehyde (cherry, almond); veratraldehyde (vanilla); 2,6-dimethyl-5-heptenal, i.e. melonal (melon); 2-6-dimethyloctanal (green fruit); and 2-dodecenal (citrus, mandarin); cherry; grape; mixtures thereof; and the like. [0052]
  • The amount of flavoring employed is normally a matter of preference subject to such factors as flavor type, individual flavor, and strength desired. Thus, the amount may be varied in order to obtain the result desired in the final product. Such variations are within the capabilities of those skilled in the art without the need for undue experimentation. In general, amounts of about 0.1 to about 30 wt. % are useable with amounts of about 10 to about 25 wt. % being preferred. [0053]
  • The compositions of this invention can also contain coloring agents or colorants. The coloring agents are used in amounts effective to produce the desired color. The coloring agents useful in the present invention, include pigments such as titanium dioxide, which may be incorporated in amounts of up to about 5 wt. %, and preferably less than about 1 wt. %. Colorants can also include natural food colors and dyes suitable for food, drug and cosmetic applications. These colorants are known as FD&C dyes and lakes. The materials acceptable for the foregoing spectrum of use are preferably water-soluble, and include FD&C Blue No. 2, which is the disodium salt of 5,5-indigotindisulfonic acid. Similarly, the dye known as Green No. 1 comprises a triphenylmethane dye and is the monosodium salt of 4-[4-N-ethyl-p-sulfobenzylamino)diphenyl-methylene]-[1-N-ethyl-N-p-sulfonium benzyl)-Δ[0054] 2,5-cyclo-hexadienimine]. Additional examples include the yellow dye, known as D&C Yellow No. 10, and the dye known as FD&C Green No. 3, which comprises a triphenylmethane dye. A full recitation of all FD&C and D&C dyes and their corresponding chemical structures may be found in the Kirk-Othmer Encyclopedia of Chemical Technology, Volume 5, Pages 857-884, which text is accordingly incorporated herein by reference.
  • Methods for preparing films according to the invention are capable of encapsulating the oil ingredients within the film-forming matrix and maintaining the integrity of the film, even when the film contains oils in amounts of 10 wt. % or more. [0055]
  • In certain methods for preparing films according to the invention, the film-forming ingredients are mixed and hydrated with water separately from the water-soluble ingredients, which are mixed in aqueous solution separately from the organic ingredients (i.e., oils) and surfactants. In these methods, the final formulation is preferably produced by mixing the film-forming phase with the aqueous phase, then mixing in the organic phase, which includes surfactants, such as Polysorbate 80 and Atmos 300 (i.e., Atlas 3000). [0056]
  • The resulting formulation is cast on a suitable substrate and dried to form a film. The film is preferably air-dried or dried under warm air and cut to a desired dimension, packaged and stored. The film preferably contains about 3% to about 8% moisture after drying. [0057]
  • The film-forming phase can include pullulan and stabilizing agents such as xanthan gum, locust bean gum and carrageenan. These ingredients are mixed and then hydrated in water for about 2 to about 48 hours to form a gel. The water is heated to a temperature of about 25 to about 45+ C. to promote hydration. The amount of water is about 40 to 80 % of the gel. The resulting hydrated gel is then chilled to a temperature of about 20 to about 30° C. for about 2 to about 48 hours. The water is preferably deionized. [0058]
  • The aqueous phase can include ingredients such as coloring agent(s), copper gluconate and sweetener. The water is preferably deionized and the amount of water used is about 5 to about 80 wt. % of the final gel mixture. [0059]
  • If sodium saccharine and copper gluconate are both ingredients in the formulation, it is preferable to dissolve them separately in solution to avoid precipitation. [0060]
  • In a preferred method of producing films according to the invention, it is possible to hydrate the film-forming ingredients and combine all of the ingredients without heating. The preferred method of producing films comprises: (a) dissolving the water-soluble ingredients in water to form an aqueous mixture; (b) mixing the film-forming ingredients together in powder form to form a powder mixture; (c) adding the powder mixture to the aqueous mixture to form a hydrated polymer gel; (d) stirring the hydrated polymer at room temperature for about 1 to about 48 hours; (e) mixing the hydrophobic ingredients and surfactants to form an oil phase; (f) adding the oil phase to the hydrated polymer gel and mixing until uniform; (g) casting the uniform mixture on a suitable substrate; and (h) drying the cast mixture to form a film. [0061]
  • The preferred method can be conducted without hydrating the film-forming ingredients in hot water. Heating the ingredients increases energy costs in the manufacturing process. Moreover, heating results in undesirable losses of volatile ingredients to evaporation, which also affects the composition of the formulation. Further, mixing the oils in two steps minimizes the amount of flavor lost. [0062]
  • While not wishing to be bound by any theories, it is believed that the film-forming ingredients can be hydrated and mixed without heating due to an ionic effect known as the Donnan equilibrium. Hydrating the film-forming agents in the presence of electrolytes in solution effectively lowers the viscosity of the polymer gel being formed, thus increasing the efficiency of the hydrating process. The electrolytes are provided by the water-soluble ingredients of the formulation, which are dissolved in the hydration solution prior to addition of the film-forming ingredients. [0063]
  • It is preferable to avoid adding both copper gluconate and saccharin to the aqueous solution, as a precipitate will form. Thus, it is preferred to combine sweeteners other than saccharin with copper gluconate. [0064]
  • The invention will be illustrated in more detail with reference to the following Examples, but it should be understood that the present invention is not deemed to be limited thereto. [0065]
  • EXAMPLE 1 Antimicrobial/Wound-Healing Film
  • [0066]
    NUMBER INGREDIENT WEIGHT (grams)
    1 Xanthan Gum 0.0385
    2 Locust Bean Gum 0.0770
    3 Carrageenan 0.3850
    4 Pullulan 18.5000
    5 Deionized Water 84.2500
    6 Mineral Oil 3.000
    7 Sodium Pyruvate 0.2200
    8 Vitamin E 0.2200
    9 Rendered Chicken Fat 0.2200
    10 Polysorbate 80 0.4000
    11 Atlas 3000/Atmos 300 0.4000
    12 Triclosan 0.0500
  • Ingredients 1-4 were dry mixed together and then added to ingredient 5 with further mixing to provide a gel phase. Ingredients 6-12 were mixed to uniformity in a separate container to provide an oil phase. The oil phase was then added to the gel phase with mixing and stored overnight. [0067]
  • The next day, the mixture was further mixed, poured on a mold and cast to form a film of a desired thickness at room temperature. The film was dried under warm air and cut to a desired dimension for testing. [0068]
  • The resulting film was slightly opaque and adhered to wet skin. [0069]
  • EXAMPLE 2 Antimicrobial/Wound-Healing Film
  • [0070]
    NUMBER INGREDIENT WEIGHT (grams)
    1 Xanthan Gum 0.035
    2 Locust Bean Gum 0.070
    3 Carrageenan 0.350
    4 Pullulan 18.000
    5 Deionized Water 75.755
    6 Tween 80 0.400
    7 Atlas 3000/Atmos 300 0.400
    8 Polymyxin B Sulfate 0.0035
    9 Bacitracin Zinc 0.0319
    10 Neomycin Sulfate 0.030
    11 Petrolatum, White 4.135
    12 Vitamin E 0.100
    13 Cocoa Butter 0.120
    14 Olive Oil 0.180
    15 Cottonseed Oil 0.300
    16 Sodium Pyruvate 0.100
  • Ingredients 1-4 were dry mixed together and then added to ingredient 5 with further mixing to provide a gel phase. Ingredients 8-16 were added to the gel phase in the form of 5.0 grams of Neosporin™ (Warner-Lambert Company, Morris Plains, N.J.) along with ingredients 6-7. The ingredients were mixed, poured on a mold and cast to form a film of a desired thickness at room temperature. The film was dried under warm air and cut to a desired dimension for testing. [0071]
  • The resulting film was not difficult to remove from the backing, but adhered to wet skin well. The film dried to a clear and shiny protective film on the skin. [0072]
  • EXAMPLE 3 Anesthetic Film
  • [0073]
    NUMBER INGREDIENT WEIGHT (grams)
    1 Xanthan Gum 0.0385
    2 Locust Bean Gum 0.077
    3 Carrageenan 0.385
    4 Pullulan 18.5
    5 Deionized Water 54.25
    6 Deionized Water 30
    7 BHT (hydroxybutyl toluene) 0.03
    8 Mineral Oil 3.0
    9 Lidocaine 1.2
    10 Polysorbate 80 0.4
    11 Atlas 3000/Atmos 300 0.4
  • Ingredients 1-4 were dry mixed together and then added to ingredient 5 with further mixing to provide a gel phase. Ingredients 6-7 were mixed together in a separate container to provide an aqueous phase. Ingredients 8-11 were mixed to uniformity in a separate container to provide an oil phase. The aqueous phase was added to the gel phase, and then the oil phase was added to the gel/aqueous phase mixture with mixing. [0074]
  • The mixture was further mixed, poured on a mold and cast to form a film of a desired thickness at room temperature. The film was dried under warm air and cut to a desired dimension. [0075]
  • EXAMPLE 4 Antimicrobial/Wound-Healing Film
  • [0076]
    NUMBER INGREDIENT WEIGHT (grams)
    1 Xanthan Gum 0.0385
    2 Locust Bean Gum 0.077
    3 Carrageenan 0.385
    4 Pullulan 18.5
    5 Deionized Water 54.25
    6 Copper Gluconate 0.4
    7 Deionized Water 30
    8 Mineral Oil 3.0
    9 Sodium Pyruvate 0.22
    10 Vitamin E 0.22
    11 Rendered Chicken Fat 0.22
    12 Polysorbate 80 0.4
    13 Atlas 3000/Atmos 300 0.4
  • Ingredients 1-4 were dry mixed together and then added to ingredient 5 with further mixing to provide a gel phase. Ingredients 6-7 were mixed together in a separate container to provide an aqueous phase. Ingredients 8-13 were mixed to uniformity in a separate container to provide an oil phase. The aqueous phase was added to the gel phase, and then the oil phase was added to the gel/aqueous phase mixture with mixing. [0077]
  • The mixture was further mixed, poured on a mold and cast to form a film of a desired thickness at room temperature. The film was dried under warm air and cut to a desired dimension. [0078]
  • While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof. [0079]

Claims (25)

What is claimed is:
1. A bioadhesive composition comprising pullulan, pyruvate, an antioxidant, and a mixture of saturated and unsaturated fatty acids adapted to resuscitate injured mammalian cells.
2. The composition according to claim 1, wherein said pyruvate is selected from the group consisting of pyruvic acid, lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, methyl pyruvate, α-ketoglutaric acid, pharmaceutically acceptable salts of pyruvic acid, prodrugs of pyruvic acid, and mixtures thereof.
3. The composition according to claim 2, wherein said pyruvate is sodium pyruvate.
4. The composition according to claim 1; wherein said antioxidant is selected from the group consisting of all forms of Vitamin A; all forms of carotene; all forms of Vitamin C; all forms of Vitamin E; Vitamin E esters which readily undergo hydrolysis to Vitamin E; prodrugs of Vitamin A, carotene, Vitamin C, and Vitamin E; pharmaceutically acceptable salts of Vitamin A, carotene, Vitamin C, and Vitamin E; and mixtures thereof.
5. The composition according to claim 4, wherein said antioxidant is Vitamin E acetate.
6. The composition according to claim 1, wherein said mixture of saturated and unsaturated fatty acids comprises animal and vegetable fats and waxes.
7. The composition according to claim 6, wherein said mixture of saturated and unsaturated fatty acids is selected from the group consisting of human fat, chicken fat, cow fat, sheep fat, horse fat, pig fat, and whale fat.
8. The composition according to claim 7, wherein said mixture of saturated and unsaturated fatty acids comprises lauric acid, myristic acid, myristoleic acid, pentadecanoic acid, palmitic acid, palmitoleic acid, margaric acid, margaroleic acid, stearic, oleic acid, linoleic acid, linolenic acid, arachidic acid, and gadoleic acid.
9. The composition according to claim 1, wherein said pullulan is present in an amount of about. 0.1 to about 80 wt. %.
10. The composition according to claim 1, wherein said pyruvate is present in an amount of about 10 to about 50 wt. %.
11. The composition according to claim 1, wherein said antioxidant is present in an amount of about 0.1 to about 40 wt. %.
12. The composition according to claim 1, wherein said mixture of saturated and unsaturated fatty acids is present in an amount of about 10 to about 50 wt. %.
13. The composition of claim 1, further comprising polymyxin B sulfate, bacitracin zinc, and neomycin sulfate.
14. The composition of claim 13, wherein said polymyxin B sulfate is present in an amount of about 1000 to about 15,000 units/gm, the bacitracin zinc is present in an amount of about 100 to about 1,500 units/gm, and the neomycin sulfate is present in an amount of about 1 to about 15 mg/gm.
15. The composition of claim 14, wherein said pullulan is present in an amount of about 40 to about 80 wt. %, said pyruvate is present in an amount of about 10 to about 50 wt. %, said antioxidant is present in an amount of about 0.1 to about 40 wt. %, and said mixture of saturated and unsaturated fatty acids is present in an amount of about 10 to about 50 wt. %.
16. The composition of claim 1, further comprising an antimicrobially effective amount of at least one essential oil selected from the group consisting of thymol, methyl salicylate, eucalyptol and menthol.
17. The composition of claim 16, comprising about 40 to about 80 wt. % pullulan, about 10 to about 50 wt. % of said pyruvate, about 0.1 to about 40 wt. % of said antioxidant, about 10 to about 50 wt. % of said mixture of saturated and unsaturated fatty acids, about 0. 1 to about 4 wt. % thymol, about 0.1 to about 4 wt. % methyl salicylate, about 0.1 to about 4 wt. % eucalyptol, about 0.1 to about 15 wt. % menthol, and about 0.1 to about 5 wt. % copper gluconate.
18. The composition of claim 1, further comprising about 0.01 to about 5 wt. % of at least one stabilizing agent, 0 to about 0.1 wt. % of at least one of at least one coloring agent, about 0.1 to about 8 wt. % of water, 0 to about 15 wt. % of at least one sweetening agent, 0 to about 15 wt. % of at least one flavoring agent, 0 to about 4 wt. % of at least one cooling agent, and about 0.1 to about 5 wt. % of at least one surfactant.
19. The composition of claim 18, wherein said least one stabilizing agent is selected from the group consisting of xanthan gum, locust bean gum and carrageenan, said at least one sweetening agent is selected from the group consisting of saccharin, aspartame and acesulfame K, said at least one cooling agent is physcool, and said at least one surfactant is selected from the group consisting of Polysorbate 80 and Atmos 300.
20. The composition of claim 1, in a form of a film that does not substantially adhere to itself.
21. The composition of claim 1, free of glycerin and sorbitol.
22. The composition of claim 1, free of humectants.
23. The composition of claim 1, wherein a total oil content of said composition is at least about 15 wt. %.
24. The composition of claim 1, wherein a total moisture content of said composition is about 3 wt. % to about 8 wt. %.
25. A method for treating a wound, said method comprising applying to said wound a composition according to claim 1.
US09/978,152 1999-02-26 2001-10-16 Bioadhesive antibacterial wound healing composition Abandoned US20020077315A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/978,152 US20020077315A1 (en) 1999-02-26 2001-10-16 Bioadhesive antibacterial wound healing composition
US10/925,548 US20050020537A1 (en) 1999-02-26 2004-08-25 Bioadhesive antibacterial wound healing composition

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12178499P 1999-02-26 1999-02-26
PCT/US2000/002079 WO2000050095A1 (en) 1999-02-26 2000-01-27 Bioadhesive antibacterial wound healing composition
USPCT/US00/02079 2000-01-27
US09/511,869 US6329343B1 (en) 1999-02-26 2000-02-25 Bioadhesive antibacterial wound healing composition
US09/978,152 US20020077315A1 (en) 1999-02-26 2001-10-16 Bioadhesive antibacterial wound healing composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/511,869 Continuation US6329343B1 (en) 1999-02-26 2000-02-25 Bioadhesive antibacterial wound healing composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/925,548 Continuation US20050020537A1 (en) 1999-02-26 2004-08-25 Bioadhesive antibacterial wound healing composition

Publications (1)

Publication Number Publication Date
US20020077315A1 true US20020077315A1 (en) 2002-06-20

Family

ID=22398769

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/511,869 Expired - Lifetime US6329343B1 (en) 1999-02-26 2000-02-25 Bioadhesive antibacterial wound healing composition
US09/978,152 Abandoned US20020077315A1 (en) 1999-02-26 2001-10-16 Bioadhesive antibacterial wound healing composition
US10/925,548 Abandoned US20050020537A1 (en) 1999-02-26 2004-08-25 Bioadhesive antibacterial wound healing composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/511,869 Expired - Lifetime US6329343B1 (en) 1999-02-26 2000-02-25 Bioadhesive antibacterial wound healing composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/925,548 Abandoned US20050020537A1 (en) 1999-02-26 2004-08-25 Bioadhesive antibacterial wound healing composition

Country Status (12)

Country Link
US (3) US6329343B1 (en)
EP (1) EP1154804B1 (en)
JP (1) JP2002537070A (en)
AR (1) AR022722A1 (en)
AT (1) ATE386554T1 (en)
AU (1) AU753292B2 (en)
CA (1) CA2355241A1 (en)
CO (1) CO5160247A1 (en)
DE (1) DE60038100T2 (en)
NZ (1) NZ513711A (en)
WO (1) WO2000050095A1 (en)
ZA (1) ZA200104742B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004792A2 (en) * 2002-07-03 2004-01-15 Mölnlycke Health Care Ab Wound bandage comprising a non-enzymatic antioxidant
US20070224271A1 (en) * 2006-03-21 2007-09-27 Marraccini Philip A Healing powder and method of use thereof
WO2010135656A2 (en) * 2009-05-22 2010-11-25 Delaval Holding Ab Barrier film-forming compositions and methods of use
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
WO2020252201A1 (en) * 2019-06-13 2020-12-17 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4035258B2 (en) * 1999-05-10 2008-01-16 花王株式会社 Skin preparation
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
US7402323B2 (en) * 2002-08-21 2008-07-22 Akpharma, Inc. Compositions and methods for treating skin conditions
US6708826B1 (en) 2003-04-30 2004-03-23 Warner-Lambert Company, Llc Packaged supply of individual doses of a personal care product
US20050042266A1 (en) * 2003-08-21 2005-02-24 Closure Medical Corporation Cyanoacrylate compositions containing anti-microbial agent
US20070218114A1 (en) * 2004-06-12 2007-09-20 Passionfor Life Healthcare Limited Soluble Strip for Oral or Topical Administration
US7334538B1 (en) * 2004-07-27 2008-02-26 Aquascience Research Group, Inc. Topical medicants for aquatic animals
EP1877041A2 (en) * 2005-04-29 2008-01-16 Cubist Pharmaceuticals, Inc. Therapeutic compositions
EP1931859B1 (en) 2005-10-06 2012-11-07 Alstom Technology Ltd Guide blade arrangement of a non-positive-displacement machine
US20080107743A1 (en) * 2006-11-02 2008-05-08 Akpharma Inc. Composition and method for enhancing skin cell growth, proliferation and repair
BRPI0811052A2 (en) 2007-04-12 2015-01-27 Univ Minnesota ISCHEMIA / REPERFUSION PROTECTION COMPOSITIONS AND METHODS OF USE.
WO2008154141A2 (en) * 2007-05-22 2008-12-18 Prelief Inc. Compositions and methods for preventing, minimizing and healing skin irritation and trauma
DE102007030103A1 (en) * 2007-06-28 2009-01-02 Bode Chemie Gmbh & Co. Kg Use of a synergistic composition as a therapeutic or cosmetic agent
US7879798B1 (en) 2007-08-24 2011-02-01 Regenicel, Inc. Composition for indolent wound healing and methods of use therefor
CN103153290B (en) * 2010-10-11 2018-01-16 普渡研究基金会 Contribute to the anti-microbial agents of wound healing
GB201120724D0 (en) * 2011-12-01 2012-01-11 Gauthier Rene System and method for alleviating the appearance of scars and/or scar tissue
US9173941B1 (en) 2012-08-02 2015-11-03 Jeff Shear Sustained release bittering composition
US9579388B2 (en) 2012-11-29 2017-02-28 Rene Gauthier System and method for alleviating the appearance of scars and/or scar tissue
US20190000876A1 (en) * 2015-09-29 2019-01-03 Tecuro Ag Stabilized antiseptic preparations
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4245689A (en) 1978-05-02 1981-01-20 Georgia Bonded Fibers, Inc. Dimensionally stable cellulosic backing web
US4562020A (en) * 1982-12-11 1985-12-31 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Process for producing self-supporting glucan film
JPS63109865A (en) * 1986-06-23 1988-05-14 東洋製薬化成株式会社 Pullulan film preparation containing drug as effective component
CA1287584C (en) * 1986-09-02 1991-08-13 Seiichi Komori Wound-healing preparations
JPS63220876A (en) * 1987-03-10 1988-09-14 日本曹達株式会社 Wound protecting agent
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5663208A (en) * 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
JPH0565222A (en) * 1991-09-09 1993-03-19 Fuji Capsule Kk Film containing pullulan blended therein for capsule and capsule
CA2123678A1 (en) * 1991-11-26 1993-06-10 Alain Martin Wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
WO1995022354A1 (en) * 1994-02-18 1995-08-24 Kanebo, Ltd. Wound covering material
JP3583166B2 (en) 1994-06-27 2004-10-27 興和株式会社 Powder preparation for damaged skin repair

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004792A2 (en) * 2002-07-03 2004-01-15 Mölnlycke Health Care Ab Wound bandage comprising a non-enzymatic antioxidant
US20050287192A1 (en) * 2002-07-03 2005-12-29 Hakan Nygren Wound bandage comprising a non-enzymatic antioxidant
WO2004004792A3 (en) * 2002-07-03 2007-11-01 Moelnlycke Health Care Ab Wound bandage comprising a non-enzymatic antioxidant
US20070224271A1 (en) * 2006-03-21 2007-09-27 Marraccini Philip A Healing powder and method of use thereof
US7294350B2 (en) * 2006-03-21 2007-11-13 Marraccini Philip A Healing powder and method of use thereof
WO2010135656A2 (en) * 2009-05-22 2010-11-25 Delaval Holding Ab Barrier film-forming compositions and methods of use
WO2010135656A3 (en) * 2009-05-22 2011-04-21 Delaval Holding Ab Barrier film-forming compositions and methods of use
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US8545896B2 (en) 2011-09-29 2013-10-01 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
WO2020252201A1 (en) * 2019-06-13 2020-12-17 Aesthetics Biomedical, Inc. Biologic preserving composition and methods of use

Also Published As

Publication number Publication date
AR022722A1 (en) 2002-09-04
EP1154804B1 (en) 2008-02-20
AU3351600A (en) 2000-09-14
EP1154804A1 (en) 2001-11-21
US6329343B1 (en) 2001-12-11
CO5160247A1 (en) 2002-05-30
JP2002537070A (en) 2002-11-05
NZ513711A (en) 2004-01-30
WO2000050095A1 (en) 2000-08-31
DE60038100D1 (en) 2008-04-03
US20050020537A1 (en) 2005-01-27
ATE386554T1 (en) 2008-03-15
AU753292B2 (en) 2002-10-17
ZA200104742B (en) 2002-09-11
CA2355241A1 (en) 2000-08-31
DE60038100T2 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
US6329343B1 (en) Bioadhesive antibacterial wound healing composition
US10751299B2 (en) Cannabinoid and menthol compositions and methods
JP2002511057A (en) Topical drug formulation
WO2014186742A2 (en) Anhydrous hydrogel composition
US10813889B2 (en) Cannabinoid and menthol compositions and methods
JP2006503003A (en) How to make a dosage form that can be taken orally
CN108159024B (en) Sustained-release patch for treating oral ulcer and preparation method thereof
EP2528609B1 (en) Propolis and process for the treatment thereof and end products formed therefrom
US20200069604A1 (en) Cannabinoid and anesthetic compositions and methods
US20210220292A1 (en) Cannabinoid and anesthetic compositions and methods
US10966924B2 (en) Veterinary cannabinoid, menthol and anesthetic compositions and methods
CN109771395B (en) Oral mucosa agent containing quercetin and preparation method thereof
EP2440179B1 (en) Chitosan oligosaccharide-based compositions
US20210000899A1 (en) Veterinary cannabinoid and menthol compositions and methods
MXPA01005826A (en) Bioadhesive antibacterial wound healing composition
US11344495B2 (en) Veterinary cannabinoid, menthol and anesthetic compositions and methods
WO2021177937A1 (en) Cannabinoid and menthol compositions and methods
WO2021177939A1 (en) Veterinary cannabinoid, menthol and anesthetic compositions and methods
WO2021177938A1 (en) Veterinary cannabinoid and menthol compositions and methods
WO2020051059A1 (en) Veterinary cannabinoid, menthol and anesthetic compositions and methods
CA2390841A1 (en) Drug preparations

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION